Active Ingredient(s): Lanadelumab (shp643)
FDA Approved: * August 23, 2018
Pharm Company: * DYAX CORP.

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Takhzyro Overview

Lanadelumab (INN; trade name Takhzyro) is a human monoclonal antibody (class IgG1 kappa)[2] that targets plasma kallikrein (pKal)[3] in order to promote prevention of angioedema in patients with hereditary angioedema.[4][5] Lanadelumab, was approved in the United States as the first monoclonal antibody indicated for prophylactic treatment to prevent hereditary angioedema (HAE) attacks.[6][7] Takhzy...

Read more Takhzyro Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Lanadelumab

Recent Takhzyro Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Lanadelumab (shp643)
  • Injection: 300mg/ml(150mg/ml)
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Takhzyro: (1 result)

Sorted by National Drug Code
  • 47783-644 Takhzyro 300 mg/2ml Subcutaneous Injection, Solution by Dyax Corp.

Other drugs which contain Lanadelumab (shp643) or a similar ingredient: (1 result)